XCUR
NASD Exicure, Inc.$1.07 ↑ +0.04 (+3.88%) Trading Up from the previous close of $1.03, $0.23 below the day’s high of $1.30
- YTD change
- -80.26%
- vs 20-day SMA
- -7.14%
- vs 200-day SMA
- -63.79%
Price ranges
Price & Performance
-2.65 (-70.28%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.9% away from all-time highs of $975.00
- XCUR is down 80% since the beginning of the year
- XCUR is down 76% over the past 12 months
- XCUR is down 13% over the past 1 month
- 1% of all XCUR investors are betting against XCUR
XCUR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -76.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.07
- Last 5 days
- +1.90%
- vs 8-day SMA
- -2.28%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
